Related Experiment Videos
Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules
1Dipartimento di Scienze Farmacobiologiche, Facoltà di Farmacia, University of Catanzaro, Complesso Ninì Barbieri, Roccelletta di Borgia, 88021 Catanzaro, Italy.
Molecular and Cellular Endocrinology
|June 5, 2003
Summary
Lower expression of adenylyl cyclase (AC) type VI in hyperfunctioning thyroid nodules may counteract activating mutations. This finding suggests a novel mechanism influencing nodule phenotype, independent of common mutations.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Hyperfunctioning thyroid nodules often harbor mutations activating the cAMP pathway.
- Alternative mechanisms may regulate nodule activity, counteracting these mutations.
Purpose of the Study:
- To investigate adenylyl cyclase (AC) types III and VI expression in hyperfunctioning thyroid nodules.
- To correlate AC expression with TSH receptor (TSHR) or gsp mutations and mRNA levels.
Main Methods:
- Western blot analysis of AC III and VI protein expression in 18 nodules.
- RT-PCR to quantify AC III and VI mRNA levels in 12 samples.
- Mutation analysis for TSHR or gsp in 12 samples.
Main Results:
- Adenylyl cyclase (AC) type VI expression was significantly lower in nodules compared to adjacent normal tissue (P=0.014).
- AC III expression showed no significant difference between nodular and normal tissue.
- AC protein levels generally correlated with mRNA transcripts, and AC III and VI expression correlated positively within nodules.
Conclusions:
- Diminished adenylyl cyclase (AC) type VI expression may contribute to hyperfunctioning thyroid nodules.
- This mechanism appears independent of TSHR or gsp mutations, suggesting a distinct pathway influencing nodule phenotype.